
    
      GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4
      weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of
      administration is 14 times.

        1. Control group (placebo): 30 subjects

        2. Study group 1 (GV1001 0.56 mg): 30 subjects

        3. Study group 2 (GV1001 1.12 mg): 30 subjects.
    
  